Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Chinese Journal of Cancer Research
Metadata
Title
Short hairpin RNA-mediated MDR1 gene silencing increases apoptosis of human ovarian cancer cell line A2780/taxol
Authors
Hui Xu
Fan-zhen Hong
Su Li
Ping Zhang
Lin Zhu
Publication date
01-06-2012
Publisher
Chinese Anti-Cancer Association
Published in
Chinese Journal of Cancer Research / Issue 2/2012
Print ISSN: 1000-9604
Electronic ISSN: 1993-0631
DOI
https://doi.org/10.1007/s11670-012-0138-3

Other articles of this Issue 2/2012

Chinese Journal of Cancer Research 2/2012 Go to the issue

Original Article

Effects of anastrozole combined with Shuganjiangu decoction on osteoblast-like cell proliferation, differentiation and OPG/RANKL mRNA expression

Review

Lymph node metastases and prognosis in penile cancer

Case Report

Sellar chordoma presenting as pseudo-macroprolactinoma with unilateral third cranial nerve palsy

Original Article

Antiproliferative effects of zinc-citrate compound on hormone refractory prostate cancer

Original Article

Overexpression and immunosuppressive functions of transforming growth factor 1, vascular endothelial growth factor and interleukin-10 in epithelial ovarian cancer

Original Article

Ent-11α-hydroxy-15-oxo-kaur-16-en-19-oic-acid inhibits growth of human lung cancer A549 cells by arresting cell cycle and triggering apoptosis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits